Carcinoid Syndrome

Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors

Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors

By

Results of the double-blinded and initial open-label phases of the ELECT Study demonstrate the effectiveness of lanreotide in controlling diarrhea and flushing in patients with NETs presenting with carcinoid syndrome.

Cost of Care Significantly Increased With Carcinoid Syndrome in NETs

Cost of Care Significantly Increased With Carcinoid Syndrome in NETs

By

Development of carcinoid syndrome has a profound effect on cost of care for patients with neuroendocrine tumors (NETs).

FDA Approves Supplemental Indication for Lanreotide Depot for Carcinoid Syndrome

FDA Approves Supplemental Indication for Lanreotide Depot for Carcinoid Syndrome

By

Patients who receieved lanreotide depot had a significantly lower percentage of days when rescue octreotide was used compared with placebo.

Lanreotide Eases Carcinoid Syndrome Symptoms in All Patients

Lanreotide Eases Carcinoid Syndrome Symptoms in All Patients

By

Lanreotide decreased the proportion of days patients had flushing and diarrhea compared with placebo, even in patients previously responsive to rescue therapy with octreotide.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs